Search results for "LIVER DISEASES"

showing 10 items of 223 documents

Evolution of patients’ socio-behavioral characteristics in the context of DAA: Results from the French ANRS CO13 HEPAVIH cohort of HIV-HCV co-infecte…

2018

International audience; BACKGROUND:Direct-acting antivirals (DAA) have dramatically increased HCV cure rates with minimal toxicity in HIV-HCV co-infected patients. This study aimed to compare the socio-behavioral characteristics of patients initiating pegylated-interferon (PEG-IFN)-based HCV treatment with those of patients initiating DAA-based treatment.METHODS:ANRS CO13 HEPAVIH is a national multicenter prospective cohort started in 2005, which enrolled 1,859 HIV-HCV co-infected patients followed up in French hospital outpatient units. Both clinical/biological and socio-behavioral data were collected during follow-up. We selected patients with socio-behavioral data available before HCV tr…

RNA virusesMaleHealth BehaviorSocial Scienceslcsh:MedicineHIV InfectionsHepacivirusGeographical locationsChronic Liver Disease0302 clinical medicineRisk FactorsPrevalencePsychologyAlcohol consumptionProspective Studies030212 general & internal medicineYoung adultProspective cohort studylcsh:SciencePathology and laboratory medicinemedia_commonChronic hepatitisDrug injectionClinical Trials as TopicMultidisciplinarybiologyPharmaceuticsCoinfectionHepatitis C virusLiver Diseasesvirus diseasesMedical microbiologyMiddle AgedPrognosisHepatitis CAddicts3. Good healthEuropeBehavioral PharmacologyDrug usersVirusesCohortFemale030211 gastroenterology & hepatologyDrug therapyFrancePathogensResearch ArticleAdultDrugmedicine.medical_specialtySubstance-Related Disordersmedia_common.quotation_subjectLiver fibrosisAddictionContext (language use)Gastroenterology and HepatologyMicrobiologyAntiviral AgentsYoung Adult03 medical and health sciencesPharmacotherapyRecreational Drug UseInternal medicinemedicineHumansEuropean UnionNutritionAgedCannabisMedicine and health sciencesPharmacologyBiology and life sciencesFlavivirusesbusiness.industrylcsh:ROrganismsViral pathogensHIVbiology.organism_classificationHepatitis virusesdigestive system diseasesMicrobial pathogensDiet[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologielcsh:Q[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCannabisPeople and placesbusiness
researchProduct

ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents

2016

Objectives: To develop a consensus and provide updated recommendations on liver MR imaging and the clinical use of liver-specific contrast agents. Methods: The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) formed a multinational European panel of experts, selected on the basis of a literature review and their leadership in the field of liver MR imaging. A modified Delphi process was adopted to draft a list of statements. Descriptive and Cronbach’s statistics were used to rate levels of agreement and internal reliability of the consensus. Results: Three Delphi rounds were conducted and 76 statements composed on MR technique (n = 17), clinical application of liver-speci…

Radiology Nuclear Medicine and ImagingDelphi TechniqueStatement (logic)030218 nuclear medicine & medical imaging0302 clinical medicineNuclear Medicine and ImagingDelphi techniqueAumento da ImagemDiagnosisMedicineImagerie médicale radiologie tomographiehealth care economics and organizationsNeuroradiologySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAmedicine.diagnostic_testLiver CellLiver DiseaseContrast mediaLiver DiseasesLiver NeoplasmsBile DuctInterventional radiologyGeneral MedicineBiliary tract; Contrast media; Delphi technique; Liver; Magnetic resonance imaging; Radiology Nuclear Medicine and ImagingMagnetic Resonance ImagingLiverBiliary tractRadiology Nuclear Medicine and imagingLiver Neoplasm030220 oncology & carcinogenesisRadiologyRadiologyHumanRadiography AbdominalAdenomamedicine.medical_specialtyConsensuseducationReproducibility of ResultConsensuBiliary tract; Contrast media; Delphi technique; Liver; Magnetic resonance imaging; Adenoma Liver Cell; Bile Ducts; Consensus; Delphi Technique; Diagnosis Differential; Humans; Liver Diseases; Liver Neoplasms; Magnetic Resonance Imaging; Radiography Abdominal; Reproducibility of Results; Contrast MediaAdenoma Liver CellDiagnosis Differential03 medical and health sciencesMagnetic resonance imagingHumansAbdominalRessonância MagnéticaMeios de ContrasteComputer. Automationbusiness.industryReproducibility of ResultsMagnetic resonance imagingMr imagingClinical trialRadiographyDifferentialBiliary tractBile DuctsDifferential diagnosisbusiness
researchProduct

Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluat…

2017

Background: Few data are available on the virological and clinical outcomes of advanced liver disease patients retreated after first-line DAA failure. Aim: To evaluate DAA failure incidence and the retreatment clinical impact in patients treated in the advanced liver disease stage. Methods: Data on HCV genotype, liver disease severity, and first and second line DAA regimens were prospectively collected in consecutive patients who reached the 12-week post-treatment and retreatment evaluations from January 2015 to December 2016 in 23 of the PITER network centers. Results: Among 3,830 patients with advanced fibrosis (F3) or cirrhosis, 139 (3.6%) failed to achieve SVR. Genotype 3, bilirubin lev…

SimeprevirMaleGenetics and Molecular Biology (all)HepacivirusPediatricsGastroenterologyBiochemistry0302 clinical medicineAnimal Cells80 and overBileMedicinePublic and Occupational HealthProspective Studieslcsh:ScienceAged 80 and overAdult; Aged; Aged 80 and over; Antiviral Agents; Drug Therapy Combination; Female; Hepatitis C; Humans; Incidence; Liver Diseases; Male; Middle Aged; Prospective Studies; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)Liver DiseaseIncidenceLiver DiseasesChild HealthBloodCirrhosisPhysical SciencesRegression Analysis030211 gastroenterology & hepatologyDrug Therapy CombinationCellular TypesStatistics (Mathematics)Humanmedicine.medical_specialtyGastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesDrug TherapyHumansStatistical MethodsAgedBlood CellsBiochemistry Genetics and Molecular Biology (all)Flaviviruseslcsh:ROrganismsBiology and Life Sciencesmedicine.diseaseRegimenProspective Studie030104 developmental biologychemistryAgricultural and Biological Sciences (all)lcsh:QMathematicsDevelopmental BiologyRNA viruses0301 basic medicineDAA HCV resistanceSofosbuvirPhysiologylcsh:MedicineLiver diseasechemistry.chemical_compoundMathematical and Statistical TechniquesMedicine and Health SciencesPathology and laboratory medicineMultidisciplinaryHepatitis C virusHepatitis CMedical microbiologyMiddle AgedHepatitis CBody FluidsVirusesCombinationFemaleAnatomyPathogensResearch Articlemedicine.drugPlateletsLedipasvirAdultDaclatasvirSettore MED/12 - GASTROENTEROLOGIAHCV liver diseases Cirrhosis DAA failureResearch and Analysis MethodsInternal medicineAntiviral Agentbusiness.industryViral pathogensBilirubinCell BiologyFibrosisHepatitis virusesMicrobial pathogensSurgeryLiver functionbusiness
researchProduct

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) …

2017

Background HCV GT4 accounts for up to 20% of HCV infections worldwide. Simeprevir, given for 12 weeks as part of a 24- or 48-week combination regimen with PR is approved for the treatment of chronic HCV GT4 infection. Primary study objectives were assessment of efficacy and safety of simeprevir plus PR in treatment-naïve patients with HCV GT4 treated for 12 weeks. Primary efficacy outcome was sustained virologic response 12 weeks post-treatment (SVR12). Additional objectives included investigation of potential associations of rapid virologic response and baseline factors with SVR12. Methods This multicentre, open-label, single-arm study (NCT01846832) evaluated efficacy and safety of simepre…

SimeprevirMalePsychologie appliquéeFetge - MalaltiesHepacivirusGastroenterologyPolyethylene GlycolPolyethylene Glycols0302 clinical medicinelcsh:Science61 - MedicinaLiver DiseasesSciences bio-médicales et agricolesCirrhosisInterferonLiver Fibrosis030211 gastroenterology & hepatologyDrug Therapy CombinationViral loadBiologieHumanmedicine.medical_specialtyCiències multidisciplinàriesGenotypeSaudi ArabiaAlpha interferon:Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores]Gastroenterology and HepatologyMicrobiologyAntiviral Agents03 medical and health sciencesHumansAgedMedicine and health sciencesHepaciviruFlavivirusesInterleukinslcsh:ROrganismsInterleukinmedicine.diseaseRegimen:Digestive System Diseases::Liver Diseases [DISEASES]chemistryImmunologylcsh:QMedicaments - AdministracióDevelopmental BiologyRNA viruseslcsh:Medicinemedicine.disease_cause:Other subheadings::Other subheadings::/drug therapy [Other subheadings]Geographical Locationschemistry.chemical_compoundSimeprevirHospital Universitari Vall d’Hebron030212 general & internal medicinePathology and laboratory medicineMultidisciplinaryHepatitis C virusHepatitis CRecombinant ProteinMedical microbiologyMiddle AgedViral LoadHepatitis CRecombinant Proteins:enfermedades del sistema digestivo::enfermedades hepáticas [ENFERMEDADES]EuropeResearch DesignVirusesFemalePathogensResearch ArticleAdultAsiaAdolescentClinical Research DesignHepatitis C virusResearch and Analysis MethodsYoung AdultInternal medicineRibavirinmedicineddc:610Rapid Virologic ResponseAntiviral AgentBiology and life sciencesbusiness.industryRibavirinViral pathogensInterferon-alphaFibrosisHepatitis virusesMicrobial pathogensPeople and PlacesAdverse EventsInterferonsbusinessPLoS ONE
researchProduct

GAMLSS for high-variability data: an application to liver fibrosis case

2020

In this paper, we propose management of the problem caused by overdispersed data by applying the generalized additive model for location, scale and shape framework (GAMLSS) as introduced by Rigby and Stasinopoulos (2005). The idea of using a GAMLSS approach for handling our problem comes from the idea of Aitkin (1996) consisting in the use of an EM maximum likelihood estimation algorithm (Dempster, Laird, and Rubin, 1977) to deal with overdispersed generalized linear models (GLM). As in the GLM case, the algorithm is initially derived as a form of Gaussian quadrature assuming a normal mixing distribution. The GAMLSS specification allows the extension of the Aitkin algorithm to probability d…

Statistics and Probabilitymixture models worm plot residual analysis liver diseasesScale (ratio)Generalized additive modelliver diseases mixture models residual analysis worm plotStatistical modelProbability and statisticsGeneral MedicineVariance (accounting)ResidualMixture model01 natural sciences030218 nuclear medicine & medical imaging010104 statistics & probability03 medical and health sciences0302 clinical medicineOverdispersionEconometrics0101 mathematicsStatistics Probability and UncertaintyThe International Journal of Biostatistics
researchProduct

Intrahepatic myeloid-cell aggregates enable local proliferation of CD8+T cells and successful immunotherapy against chronic viral liver infection

2013

Chronic infection is difficult to overcome because of exhaustion or depletion of cytotoxic effector CD8(+) T cells (cytotoxic T lymphoytes (CTLs)). Here we report that signaling via Toll-like receptors (TLRs) induced intrahepatic aggregates of myeloid cells that enabled the population expansion of CTLs (iMATEs: 'intrahepatic myeloid-cell aggregates for T cell population expansion') without causing immunopathology. In the liver, CTL proliferation was restricted to iMATEs that were composed of inflammatory monocyte-derived CD11b(+) cells. Signaling via tumor-necrosis factor (TNF) caused iMATE formation that facilitated costimulation dependent on the receptor OX40 for expansion of the CTL popu…

T cellmedicine.medical_treatmentImmunologyPopulationGreen Fluorescent ProteinsMice TransgenicBiologyCD8-Positive T-LymphocytesLymphocytic ChoriomeningitisMicemedicineImmunology and AllergyCytotoxic T cellAnimalsLymphocytic choriomeningitis virusMyeloid CellseducationCell ProliferationMice Knockouteducation.field_of_studyLiver infectionCD11b AntigenMicroscopy ConfocalLiver DiseasesImmunotherapyReceptors OX40Flow CytometryMice Inbred C57BLCTL*Chronic infectionmedicine.anatomical_structureAnimals NewbornLiverToll-Like Receptor 9ImmunologyChronic DiseaseHost-Pathogen InteractionsImmunotherapyCD8Signal TransductionT-Lymphocytes CytotoxicNature Immunology
researchProduct

Autoimmunity and liver disease

1990

T-LymphocytesHuman leukocyte antigenMitochondrionmedicine.disease_causeAutoantigensAutoimmunityLiver diseaseImmune systemHLA AntigensImmunopathologymedicineAnimalsHumansAutoantibodiesAutoimmune diseaseHepatologybusiness.industryLiver DiseasesAutoantibodymedicine.diseaseMitochondriaLiverAntibodies AntinuclearImmune SystemImmunologybusinessHepatology
researchProduct

Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030

2018

Background & Aims: Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are increasingly a cause of cirrhosis and hepatocellular carcinoma globally. This burden is expected to increase as epidemics of obesity, diabetes and metabolic syndrome continue to grow. The goal of this analysis was to use a Markov model to forecast NAFLD disease burden using currently available data. Methods: A model was used to estimate NAFLD and NASH disease progression in eight countries based on data for adult prevalence of obesity and type 2 diabetes mellitus (DM). Published estimates and expert consensus were used to build and validate the model projections. Results: If obesity and…

Time FactorsDiseaseddc:616.07Liver disease0302 clinical medicineDiabetes mellitusCost of IllnessNon-alcoholic Fatty Liver DiseasePrevalenceHCCddc:616Mathematical modelseducation.field_of_studyMalalties del fetgeLiver DiseasesFatty liverBurden of diseaseNASHCardiovascular diseaseMetabolic syndromeMarkov ChainsCirrhosis030220 oncology & carcinogenesis030211 gastroenterology & hepatologyHealth care resource utilizationDiabetes mellituChinaPopulationdigestive system03 medical and health sciencesEnvironmental healthNAFLDmedicineHumansddc:610ObesityeducationDisease burdenCirrhosiHepatologybusiness.industryModels matemàticsnutritional and metabolic diseasesModels Theoreticalmedicine.diseaseObesitydigestive system diseasesDiabetes Mellitus Type 2SteatohepatitisMetabolic syndromebusiness
researchProduct

Uncommon evolutions and complications of common benign liver lesions

2018

International audience; Frequently encountered on abdominal imaging studies, the majority of common benign liver lesions are asymptomatic, confidently diagnosed by imaging, and do not require further workup, follow-up, or treatment. The increasing use of multimodality liver imaging, has allowed the recognition of uncommon evolutions of common benign liver lesions such as size changes, fibrotic regression, and content and vascularization changes, and their complications such as rupture, hemorrhage, thrombosis, extrinsic compression, and malignancy. The purpose of this pictorial review is to describe and illustrate the incidence and diagnostic features of these uncommon evolutions and complic…

Uncommon evolutionsmedicine.medical_specialtyBenign liver lesionComplications[SDV]Life Sciences [q-bio]UrologyComputed tomographyMalignancyAsymptomaticExtrinsic compression03 medical and health sciences0302 clinical medicineInternal medicinemedicineBenign liver lesionsHumansRadiology Nuclear Medicine and imagingComputed tomographyRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industryLiver DiseasesLiver NeoplasmsGastroenterologyMagnetic resonance imagingHepatologymedicine.diseaseMagnetic Resonance ImagingThrombosis3. Good healthLiver030220 oncology & carcinogenesis030211 gastroenterology & hepatologyRadiologyDifferential diagnosismedicine.symptomTomography X-Ray ComputedbusinessComplicationUncommon evolutionAbdominal Radiology
researchProduct

Numerical Taxonomy of Vibrionaceae Isolated from Cultured Amberjack ( Seriola dumerili ) and Surrounding Water

2003

A numerical taxonomic study was performed on 148 isolates of Gram-negative, heterotrophic, facultative anaerobic bacteria isolated from amberjack (Seriola dumerili) and its surrounding culture water. The study included 30 type and reference strains belonging to genera Vibrio, Listonella, and Photobacterium. The strains were characterized by 109 morphological, biochemical, physiological, and nutritional tests. Cluster analysis of similarity matrices obtained with S(SM) and S(J) coefficients was carried out. UPGMA (unweighted pair group mathematical average) analysis defined 11 phena at S(SM) values > or = 86%. Nine phena were identified as Vibrio alginolyticus, V. fischeri, V. harveyi, V. ca…

Vibrio alginolyticusbiologyLiver DiseasesVibrionaceaeGeneral Medicinebiology.organism_classificationPhotobacteriumApplied Microbiology and BiotechnologyMicrobiologyVibrioSeriola dumeriliPerciformesMicrobiologyFish DiseasesPhenotypePhotobacterium damselaeVibrionaceaeAnimalsKidney DiseasesSeawaterAmberjackPhylogenyListonellaCurrent Microbiology
researchProduct